Literature DB >> 11050052

Different costimulation signals used by CD4(+) and CD8(+) cells that independently initiate rejection of allogenic hepatocytes in mice.

D Gao1, J Li, C G Orosz, G L Bumgardner.   

Abstract

The current study evaluated the role of CD40/CD40 ligand (CD40L) and CD28/B7 costimulation signals during alloimmune responses independently mediated by CD4(+) or CD8(+) T cells. Allogeneic hepatocytes were transplanted into CD8 or CD4 knock out (KO) mice under cover of costimulatory blockade. Rejection of FVB/N (H-2(q)) hepatocytes occurred by day 10 posttransplant in untreated CD8 or CD4 KO (H-2(b)) mice. Treatment of CD8 or CD4 KO mice with anti-CD40L monoclonal antibody (mAb; MR1) resulted in significant prolongation of hepatocyte survival indicating that CD40/CD40L interactions were critical in both CD4(+) and CD8(+) T-cell initiated hepatocyte rejection. Anti-CD40L mAb also prolonged hepatocyte survival in B-cell KO (H-2(b)) mice, indicating that the efficacy of CD40/CD40L blockade in preventing hepatocyte rejection was B-cell (and antibody) independent. In contrast, treatment with CTLA4 fusion protein (CTLA4Ig), prolonged hepatocyte survival in CD8 KO but not CD4 KO mice, showing that CD28/B7 interactions were important in CD4(+) but not CD8(+) T-cell initiated hepatocyte rejection. Under selected circumstances, such as in CD40 KO mice, both CD4(+) and CD8(+) T cells mediate hepatocyte rejection in the absence of CD40/CD40L costimulation and without a significant contribution from CD28/B7 costimulation signals. These results highlight the disparate roles of CD40/CD40L and CD28/B7 costimulation signals in CD4(+) versus CD8(+) T-cell mediated immune responses to allogeneic hepatocytes. The CD4(+) T-cell independent, CD40L-sensitive, CD28/B7-independent pathway of CD8(+) T-cell activation in response to transplantation antigens is novel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050052     DOI: 10.1053/jhep.2000.19325

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

1.  CD4+ T lymphocytes are not necessary for the acute rejection of vascularized mouse lung transplants.

Authors:  Andrew E Gelman; Mikio Okazaki; Jiaming Lai; Christopher G Kornfeld; Friederike H Kreisel; Steven B Richardson; Seiichiro Sugimoto; Jeremy R Tietjens; G Alexander Patterson; Alexander S Krupnick; Daniel Kreisel
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

Review 2.  Immunological aspects of liver cell transplantation.

Authors:  Felix Oldhafer; Michael Bock; Christine S Falk; Florian W R Vondran
Journal:  World J Transplant       Date:  2016-03-24

3.  Invariant NKT Cells Promote the Development of Highly Cytotoxic Multipotent CXCR3+CCR4+CD8+ T Cells That Mediate Rapid Hepatocyte Allograft Rejection.

Authors:  Jason M Zimmerer; Bryce A Ringwald; Sachi R Chaudhari; Jing Han; Chelsea M Peterson; Robert T Warren; Madison M Hart; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  J Immunol       Date:  2021-11-22       Impact factor: 5.426

4.  Cytotoxic effector function of CD4-independent, CD8(+) T cells is mediated by TNF-α/TNFR.

Authors:  Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Thomas A Pham; Samiya L Saklayen; Ginny L Bumgardner
Journal:  Transplantation       Date:  2012-12-15       Impact factor: 4.939

5.  Inhibition of recall responses through complementary therapies targeting CD8+ T-cell- and alloantibody-dependent allocytotoxicity in sensitized transplant recipients.

Authors:  Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Kartika Jayashankar; Sierra F Garcia; Mahmoud Abdel-Rasoul; Nico van Rooijen; Ginny L Bumgardner
Journal:  Cell Transplant       Date:  2012-10-11       Impact factor: 4.064

6.  Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.

Authors:  K E Lunsford; K Jayanshankar; A M Eiring; P H Horne; M A Koester; D Gao; G L Bumgardner
Journal:  Am J Transplant       Date:  2008-06       Impact factor: 8.086

7.  Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens.

Authors:  Chethan Ashokkumar; Bishu Ganguly; Robert Townsend; Jaimie White; Samantha Levy; Michael Moritz; George Mazariegos; Qing Sun; Rakesh Sindhi
Journal:  Sci Rep       Date:  2015-10-16       Impact factor: 4.379

8.  Hepatocyte-induced CD4+ T cell alloresponse is associated with major histocompatibility complex class II up-regulation on hepatocytes and suppressible by regulatory T cells.

Authors:  Daphne E DeTemple; Felix Oldhafer; Christine S Falk; Chen Chen-Wacker; Constanca Figueiredo; Moritz Kleine; Wolf Ramackers; Kai Timrott; Frank Lehner; Juergen Klempnauer; Michael Bock; Florian W R Vondran
Journal:  Liver Transpl       Date:  2018-03       Impact factor: 5.799

9.  Silencing of HLA class I on primary human hepatocytes as a novel strategy for reduction in alloreactivity.

Authors:  Constança Figueiredo; Felix Oldhafer; Eva-Maria Wittauer; Marco Carvalho-Oliveira; Ali Akhdar; Oliver Beetz; Chen Chen-Wacker; Yuliia Yuzefovych; Christine S Falk; Rainer Blasczyk; Florian W R Vondran
Journal:  J Cell Mol Med       Date:  2019-06-10       Impact factor: 5.310

10.  The mouse lymph node as an ectopic transplantation site for multiple tissues.

Authors:  Junji Komori; Lindsey Boone; Aaron DeWard; Toshitaka Hoppo; Eric Lagasse
Journal:  Nat Biotechnol       Date:  2012-09-23       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.